Your browser doesn't support javascript.
loading
The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care.
Broni, Eric K; Ndumele, Chiadi E; Echouffo-Tcheugui, Justin B; Kalyani, Rita R; Bennett, Wendy L; Michos, Erin D.
Afiliación
  • Broni EK; Department of Medicine, Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Ndumele CE; Department of Medicine, Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Echouffo-Tcheugui JB; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Kalyani RR; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Bennett WL; Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Michos ED; Department of Medicine, Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. edonnell@jhmi.edu.
Curr Diab Rep ; 22(1): 11-25, 2022 01.
Article en En | MEDLINE | ID: mdl-35157237
PURPOSE OF REVIEW: Cardiovascular disease (CVD) complications constitute about 50-70% of mortality in people with diabetes. However, there remains a persistently greater relative increase in CVD morbidity and mortality in women with diabetes than in their male counterparts. This review presents recent evidence for the risks, outcomes, and management implications for women with diabetes. RECENT FINDINGS: Compared to men, women have higher BMI and more adverse cardiovascular risk profile at time of diabetes diagnosis with greater risk for coronary heart disease, stroke, vascular dementia, and heart failure. Pregnancy-specific risk factors of gestational diabetes and pre-eclampsia are associated with future type 2 diabetes (T2D) and CVD. Women with T2D may experience greater benefits than men from GLP-1 receptor agonists. Women with diabetes are at greater relative risk for CVD complications than men, with poorer outcomes, superimposed on preexisting gender disparities in social determinants of health, lower likelihood of being offered cardioprotective interventions, and enrollment in trials. Further research and the utilization of SGLT-2 inhibitors, GLP-1 receptor agonists, and other CVD prevention strategies will help reduce morbidity and mortality.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus Tipo 2 Tipo de estudio: Etiology_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Curr Diab Rep Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus Tipo 2 Tipo de estudio: Etiology_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Female / Humans / Male / Pregnancy Idioma: En Revista: Curr Diab Rep Asunto de la revista: ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos